AR030160A1 - Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion - Google Patents

Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion

Info

Publication number
AR030160A1
AR030160A1 ARP000104249A ARP000104249A AR030160A1 AR 030160 A1 AR030160 A1 AR 030160A1 AR P000104249 A ARP000104249 A AR P000104249A AR P000104249 A ARP000104249 A AR P000104249A AR 030160 A1 AR030160 A1 AR 030160A1
Authority
AR
Argentina
Prior art keywords
compound
group
hydroxamic acid
formula
manufacture
Prior art date
Application number
ARP000104249A
Other languages
English (en)
Inventor
Brien Patrick Michael O
Daniel Fred Ortwine
Joseph Armand Picard
Drago Robert Sliskovic
Christopher Alan Conrad
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR030160A1 publication Critical patent/AR030160A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de ácido hidroxámico de formula 1 o una sal farmacéuticamente aceptable de la misma, dondeX se selecciona de OH, y NHOH; d es 1 o 2; R1 se selecciona de un grupo compuesto por aquellos denominados (a), (b), y otros de acuerdo con lo descrito en la memoria descriptiva, donde R2 es seleccionado de un grupo compuesto por H, y otros de acuerdo con lo descrito en la memoria descriptiva, R3 y R4 se selecciona de un grupo compuesto por alquilo de C1-20 y otros de acuerdo con la memoria descriptiva y de sustituyentes agrupados para formar un grupo de formula empírica -(CH2)sZg-, de acuerdo con la memoria descriptiva. Una formulacion farmacéutica que comprende un compuesto de ácido hidroxámico que es un compuesto de la formula 1 mezclado con un diluyente, vehículo, o excipiente del mismo. Uso de un compuesto de la formula 1 para la fabricacion de una composicion farmacéutica para inhibir una metaloproteinasa de matriz, la que se relaciona preferentemente con artritis, esclerosis multiple, aterosclerosis, restenosis, la inflamacion y el dolor, aneurisma, cardiopatía, osteoporosis, enfermedad periodontal, ulcera de cornea, ulcera decubital, cáncer, y desordenes neurodegenerativos cronicos y agudos.
ARP000104249A 1999-08-18 2000-08-17 Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion AR030160A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14966099P 1999-08-18 1999-08-18

Publications (1)

Publication Number Publication Date
AR030160A1 true AR030160A1 (es) 2003-08-13

Family

ID=22531286

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104249A AR030160A1 (es) 1999-08-18 2000-08-17 Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion

Country Status (18)

Country Link
US (1) US6677355B1 (es)
EP (1) EP1210326B1 (es)
JP (1) JP2003507362A (es)
AR (1) AR030160A1 (es)
AT (1) ATE260251T1 (es)
AU (1) AU6764400A (es)
BR (1) BR0013390A (es)
CA (1) CA2378332A1 (es)
CO (1) CO5300407A1 (es)
DE (1) DE60008548T2 (es)
DK (1) DK1210326T3 (es)
ES (1) ES2216938T3 (es)
MX (1) MXPA01013324A (es)
PE (1) PE20010486A1 (es)
PT (1) PT1210326E (es)
TR (4) TR200202163T2 (es)
UY (1) UY26302A1 (es)
WO (1) WO2001012592A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
ATE478864T1 (de) 2004-07-16 2010-09-15 Schering Corp Hydantoinderivate zur behandlung von entzündlichen erkrankungen
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CN101573333B (zh) * 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CL2008001257A1 (es) * 2007-05-04 2008-07-04 Wyeth Corp Compuestos triciclicos, inhibidores de metaloproteinasas matriciales; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, aterosclerosis, cancer de pulmon, entre otras.
TW201024304A (en) 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
EP2346857B1 (en) 2008-09-24 2019-11-27 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory disorders
US8569336B2 (en) 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
EP2356111A1 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
KR20110096566A (ko) * 2008-12-05 2011-08-30 인터메드 디스커버리 게엠베하 Ｈｉｆ-1 단백질 축적의 억제제
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
CN113336670B (zh) * 2021-05-28 2023-06-02 河南大学 一种轴手性芴胺-苯酚类衍生物及其制备方法
KR102701383B1 (ko) 2022-11-11 2024-09-04 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22849A (id) * 1997-01-23 1999-12-09 Hoffmann La Roche Penghambat-penghambat sulmafida-metaloprotease
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
AU730248B2 (en) * 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
TR200202211T2 (tr) 2002-11-21
WO2001012592A2 (en) 2001-02-22
JP2003507362A (ja) 2003-02-25
US6677355B1 (en) 2004-01-13
DE60008548D1 (de) 2004-04-01
BR0013390A (pt) 2002-04-30
DE60008548T2 (de) 2004-08-05
MXPA01013324A (es) 2002-07-02
CO5300407A1 (es) 2003-07-31
UY26302A1 (es) 2000-10-31
TR200200410T2 (tr) 2002-06-21
CA2378332A1 (en) 2001-02-22
DK1210326T3 (da) 2004-06-21
ES2216938T3 (es) 2004-11-01
PT1210326E (pt) 2004-07-30
ATE260251T1 (de) 2004-03-15
TR200202164T2 (tr) 2002-11-21
PE20010486A1 (es) 2001-04-20
EP1210326A2 (en) 2002-06-05
WO2001012592A3 (en) 2001-07-05
TR200202163T2 (tr) 2002-11-21
EP1210326B1 (en) 2004-02-25
AU6764400A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
AR030160A1 (es) Compuestos de acido hidroxamico , formulacion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de dicha composicion
MX9700890A (es) 1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos.
NO843836L (no) Terapeutisk aktive sulfamatderivater
BG101308A (bg) Повърхностноактивни състави
ES8304072A1 (es) "procedimiento de preparacion de derivados de 1-fenil-1-hidroxi-etilamina".
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
ATE208397T1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
AR022423A1 (es) Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
UY27700A1 (es) Compuestos oxo - azabiclícos.
AR033335A1 (es) Compuestos de acidos 3-propil gama aminobutirico mono y di sustituidos, composicion farmaceutica que los comprende y su uso para fabricar dicha composicion
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
DK0421561T3 (da) 24-homo-vitamin-D-derivater, fremgangsmåder til fremstilling heraf, farmaceutiske præparater indeholdende disse derivater samt deres anvendelse som lægemiddel
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
AR016134A1 (es) Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritis
HU200591B (en) Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
AR008234A1 (es) Derivados de benzamidas, procedimiento para su preparacion, composiciones farmaceuticas y su uso para la preparacion de un medicamento
HUT64529A (en) Method for producing flu orinated derivatives of taxole and preparations contaxole preparations containing said compounds as active agent
ES2078507T3 (es) Medicinas y derivados de sulfonanilida.
DK1134215T3 (da) 2-oxo-imidazolidin-4-carboxylsyrehydroxaminforbindelser, som inhiberer matrixmetalloproteinaser
ES2039213T3 (es) Procedimiento para producir nuevos compuestos relacionados con espergualina.
ES2160197T3 (es) Empleo de una sal de sodio o de lisinio de derivados de amida del acido crotonico para la preparacion de un medicamento para el tratamiento de enfermedades cancerigenas.
JPS6029400B2 (ja) ジホスホノアルカンカルボン酸及びその製造法
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
FR2455590A1 (fr) Nouveaux derives d'acide 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)-benzoique, utiles notamment comme agents bloquants des recepteurs a- et b-adrenergiques, et leur procede de preparation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal